Neurocrine Biosciences Inc (NBIX)
Financial leverage ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Total assets | US$ in thousands | 3,718,700 | 3,251,400 | 2,368,700 | 2,072,500 | 1,734,700 |
Total stockholders’ equity | US$ in thousands | 2,589,700 | 2,232,000 | 1,707,800 | 1,374,000 | 1,126,200 |
Financial leverage ratio | 1.44 | 1.46 | 1.39 | 1.51 | 1.54 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $3,718,700K ÷ $2,589,700K
= 1.44
The financial leverage ratio for Neurocrine Biosciences Inc has shown a slight decreasing trend over the years, declining from 1.54 in December 2020 to 1.44 in December 2024. This indicates that the company's reliance on debt to finance its operations and growth has decreased gradually. However, the ratio remains above 1, suggesting that there is still some level of financial leverage in the company's capital structure. Overall, the trend indicates a moderate level of financial leverage that is being managed effectively by the company.
Peer comparison
Dec 31, 2024
Company name
Symbol
Financial leverage ratio
Neurocrine Biosciences Inc
NBIX
1.44
ADMA Biologics Inc
ADMA
2.43
Amgen Inc
AMGN
15.59
Bio-Techne Corp
TECH
1.31
Biogen Inc
BIIB
1.68
Gilead Sciences Inc
GILD
2.72
Halozyme Therapeutics Inc
HALO
20.68
Krystal Biotech Inc
KRYS
1.12
Moderna Inc
MRNA
1.33
Repligen Corporation
RGEN
1.43
Vericel Corp Ord
VCEL
1.57